Oligosecretary Myeloma: Prevalence and Its Clinical Significance

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02095379

Enrollment

390

Registered

2014-03-24

Start date

2013-10-31

Completion date

2014-02-28

Last updated

2014-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

oligosecretary multiple myeloma

Brief summary

In this study, the investigators aim to investigate the prevalence and clinical course of oligosecretary myeloma.

Detailed description

Oligosecretary myeloma is a subgroup of multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day). Patients with oligosecretary myeloma do not have established methods for disease monitoring and clinical informations regarding oligosecretary myeloma are still largely unknown. In this study, we aimed to investigate the prevalence and clinical course of oligosecretary myeloma.

Interventions

OTHERoligosecretary

not abvailable

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

17 Years to 90 Years

Healthy volunteers

Inclusion criteria

* a subgroup of multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day) * available clinical data

Exclusion criteria

* patients without available clinical data

Design outcomes

Primary

Measure	Time frame
Number of patients with oligosecretary myeloma among multiple myeloma patients	up to 1 year

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026